Japan Medical Dynamic Marketing, Inc. · TSE:7600
Japan Medical Dynamic Marketing — H1 FYE March 2023 Earnings Presentation
27 slides from Japan Medical Dynamic Marketing's earnings presentation, Nov 11, 2022
Slide 1: First Half Financial Results Briefing for the Fiscal Year Ending March 2023
First Half Financial Results Briefing for the Fiscal Year Ending March 2023 November 11, 2022 Japan Medical Dynamic Marketing,INC. Securities code：7600 Representative Director and President Masao Okawa Copyright © Japan Medical Dynamic Marketing, INC. All Rights Reserved.
Slide 2: Notes
Notes The forward-looking statements in this document are based on information currently available to us and certain assumptions that we consider reasonable, and are not intended as a promise by us that they will be realized. Actual results may differ materially due to various factors. Our products
Slide 3: Agenda
-Agenda- Results for the First Half of Revised Forecast for 1 . P. 4 2 ． P.18 FYE March 2023 FYE March 2023 - Consolidated net sales P. 4 Revised Full-year Forecast - P.18 Consolidated Statement of Income - Consolidated Statement of Income P. 5 Revised Full-year Forecast Consolidated Net Sales by -
Slide 4: Consolidated net sales
Consolidated net sales 22/3 H1 +12.8% 9,980 * After the application of revenue recognition standards (Millions of yen) million yen 10,000 Double-digit growth for two 8,000 consecutive quarters 6,000 Highest first-half net sales in company history 4,000 H1 YoY Change 2,000 Japan + 6.2% 0 U.S. + 23.3%
Slide 5: Consolidated Statement of Income
Consolidated Statement of Income FYE Mar 2023 H1 YoY change FYE Mar 2022 H1 Ratio Ratio to Amount of Rate of Results Results to sales change change (Millions of yen, %) sales Net sales 9,989 100.0 +1,131 +12.8 8,858 100.0 Cogs 3,370 33.7 +514 +18.0 2,856 32.2 SG & A 5,691 57.0 +748 +15.1 4,943 55.8
Slide 6: Consolidated Net Sales by Location/Product
Consolidated Net Sales by Location/Product FYE Mar 2023 H1 YoY change FYE Mar 2022 H1 Percentag Amount of Rate of Percent Results Results (Millions of yen, %) e change change age Sales in Japan 5,921 59.3 +325 +5.8 5,596 63.2 Joint 2,226 22.3 +80 +3.7 2,146 24.2 Trauma 1,922 19.2 +150 +8.5 1,772 20.
Slide 7: Sales in Japan - Joint Replacement
Sales in Japan - Joint Replacement （Millions of yen） Strength from ODEV products 22/3 H1 +3.7% THA* 2,500 Products of other companies *Total Hip Arthroplasty Highlights 2,000 • Strong growth of Entrada® Hip System • Intellijoint HIP® Navigation system Synergy from expanded introduction 1,500 Challen
Slide 8: Growth Factors for Hip Joint Sales in Japan
Growth Factors for Hip Joint Sales in Japan Surgical navigation system for total hip arthroplasty [Intellijoint HIP® navigation system] Surgical Our navigation Products system Expansion of sales of artificial hip joint products in Japan Manufactured by Intellijoint Surgical Inc. (Canada) [Intellijoi
Slide 9: New Artificial Hip Joint Product: Promontory Hip Stem
New Artificial Hip Joint Product Promontory Hip Stem Promontory Hip Stem Launch (September 2022) The cross-sectional shape of the stem is rectangular, with strong fixation expected as the corners of the stem bite into the medullary cavity of the femur. Useful in a wide range of cases, regardless
Slide 10: Sales in Japan - Trauma
Sales in Japan - Trauma （Millions of yen） 2,000 ODEV products 22/3 H1 +8.5% Femoral Neck Products of other companies fracture fixation system ODEV product 1,500 Prima Hip Screw & Other company’s product ASULOCK 1,000 500 Double-digit 0 growth 14/3 15/3 16/3 17/3 18/3 19/3 20/3 21/3 22/3 23/3 H1 H1 H
Slide 11: Sales in Japan - Spine
Sales in Japan - Spine （Millions of yen） 22/3 H1 +9.5% ODEV products ODEV product: 1,500 Products of other companies Pisces spinal system & Other company's product: BKP (KMC Kyphoplasty system) 1,000 Double-digit growth New Products Launched 500 Vusion Ti3D ARC cage (July 2022) Lynx α plate 0 (Augus
Slide 12: Vusion Ti3D ARC Cage
New Spinal Fixation Devices Vusion Ti3D ARC Cage Vusion Ti3D ARC Cage Launch (July 2022) Interbody fusion implant used during spinal fusion With a porous structure simulating cancellous bone and an optimized pore size, stable fixation and early bone union between vertebrae can be expected. Vusio
Slide 13: Lynx α Plate
New Spinal Fixation Devices Lynx α Plate Lynx α Plate Launch (August 2022) Intra-spinal fixation device and plate for cervical laminoplasty In fixing the vertebral arch with a plate and screws, a locking screw system and a characteristic plate design (which are not available in the conventional
Slide 14: Sales in U.S.
Sales in U.S. 22/3 H1 +1.9% $31.3M (Millions of dollars) 35 30 Highlights • Increase in the number of surgical cases from new customers added in the prior fiscal 25 year 20 Challenges • Temporary postponement of the 15 commencement of business with new customers due to supply chain issues • Retireme
Slide 15: Sales in U.S. – Joint Replacement
Sales in U.S. – Joint Replacement 15 Artificial Hip Joint Artificial Knee Joint $11.7M $18.7M Growth rate 22/3 H1 +4.2% 22/3 H1 +0.9% (Millions of dollars) 20 Hip > Knee Slower Growth with Knee 15 • Retirement of 3 surgeons with high surgical volume in early 2022 • Defection of one large customer to
Slide 16: Comparative YoY Analysis of Operating Profit
Comparative YoY Analysis of Operating Profit Sales in Japan +¥477 million* Personnel expenses （Millions of yen） Impact of significant Maintaining growth despite +¥108 million* depreciation of the yen: certain restrictions Strengthening human • Net sales: +¥729 million on marketing activities due to
Slide 17: Difference in H1 Financial Forecasts
Difference in H1 Financial Forecasts 23/3, H1 Change from initial forecast 23/3, H1 Ratio to Amount of Rate of Initial Ratio to Results change change forecast sales （Millions of yen , ％） sales Net sales 9,989 100.0 - 210 - 2.1 10,200 100.0 Operating profit 927 9.3 - 172 - 15.7 1,100 10.8 Ordinary pr
Slide 18: Revised Full-year Forecast: Consolidated Statement of Income
Revised Full-year Forecast Consolidated Statement of Income FYE March 2023 Change from previous year FYE March 2022 Ratio to Rate of Ratio to Forecast Amount of change Results （Millions of yen , ％） sales change sales Net sales 21,800 100.0 +2,606 +13.6 19,193 100.0 Cogs 7,450 34.2 +1,245 +20.1 6,204
Slide 19: Revised Full-year Forecast: Consolidated Net Sales by product group
Revised Full-year Forecast Consolidated Net Sales by product group FYE March 2023 Change from previous year FYE March 2022 Percen- Amount of Rate of Percen Forecast Results （Millions of yen , ％） tage change change -tage Sales in Japan 13,100 60.1 +691 +5.7 12,409 64.7 Joint 4,920 22.6 +201 +4.3 4,71
Slide 20: Compared with Previous Full-year Financial Forecast
Compared with Previous Full-year Financial Forecast FYE March 2023 Change from initial forecast FYE March 2023 Ratio to Rate of Initial Ratio to Revised forecast Amount of change （Millions of yen , ％） sales change forecast sales Net sales 21,800 100.0 - 200 - 0.9 22,000 100.0 Operating profit 2,000
Slide 21: Sales Strategy for the Second Half
Sales Strategy for the Second Half Aiming to increase operating profit by expanding sales Sales Strategy for the Second Half Key Measures to Expand Business Base “MODE2023” (FYE Mar 2022 to FYE Mar 2024) Strengthen sales of focused products in the Japan (1) Expand overseas business market ‒ Contin
Slide 22: Signing of the United Nations Global Compact (UNGC)
Topic (1) Signing of the United Nations Global Compact (UNGC) Signing the “United Nations Global Compact (UNGC)” advocated by the United Nations (Registered as a Participating Enterprise on June 23, 2022) [Certificate for Signing the United Nations Global Compact] United Nations Global Compact Headq
Slide 23: Information Disclosure based on TCFD (GHG Emissions Reduction)
Topic (2) Information Disclosure based on TCFD (GHG Emissions Reduction) Recognizing our response to climate change as one of our materiality issues, we will deepen our understanding of the risks and opportunities related to climate change impacting our business, and work to reduce scope 1 and 2 gre
Slide 24: Information Disclosure based on TCFD (Risks and Opportunities)
Topic (2) Information Disclosure based on TCFD (Risks and Opportunities) We consider delays in logistics and lost opportunities due to natural disasters as risks. In response to these risks, we will promote the decentralized storage of inventory and the use of distribution center to reduce risks and
Slide 25: Topic (3) Status of Business in China
Topic (3) Status of Business in China WOMA (Changzhou Waston Ortho Medical Appliance Co., Limited) Sales • Certified as a supplier by bidding for the central government's centralized purchasing tender with BKS manufactured by ODEV (made in U.S.A.) • Acquisition of two-year sales rights from Septembe
Slide 26: Topic (4) Status of Business in Australia
Topic (4) Status of Business in Australia Business losses related to the fiscal year ended March 2022 have been included, with minimal impact on the consolidated financial results for the fiscal year ending March 2023. Ortho Development Pty Ltd. Established as a subsidiary of U.S. Ortho Developmen
Slide 27: Contributing to Medical Care Through the Development and Sale of Advanced Medical Devices
Contributing to Medical Care Through the Development and Sale of Advanced Medical Devices. Japan Medical Dynamic Marketing,INC. E-MAIL WEB SITE Investor Relations Office ir@jmdm.co.jp https://www.jmdm.co.jp/en/
Japan Medical Dynamic Marketing — H1 FYE March 2023 Earnings Presentation on 6ix